ALVO - AbbVie keeps Humira market share near 100% despite biosimilars: report
2024-04-13 10:52:04 ET
More on AbbVie, Amgen, etc.
- AbbVie: Bulletproof Fundamentals
- AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67%
- UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut
- GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
- Pfizer unit to settle Effexor XR antitrust claims in $39M deal